Table 9.

Major RCTs and Meta-Analyses of Periprocedural Anticoagulation for Atrial Fibrillation Ablation

Publication Year	First Author	Trial Name	N	Comparison	Major Bleeding	P Value	Ischemic Stroke	P Value
Major RCTs
2014	Di Biase et al57	COMPARE	1,584	Interrupted VKA vs uninterrupted VKA	0.76% vs 0.38%	0.31	3.7% vs 0.25%	<0.001
2015	Cappato et al110	VENTURE-AF	248	Uninterrupted rivaroxaban vs uninterrupted VKA	0% vs 0.4%	NR	0% vs 0.8%	NR
2017	Calkins et al59	RE-CIRCUIT	704	Uninterrupted dabigatran vs uninterrupted VKA	1.6% vs 6.9%	<0.001	0 % vs 0.3%	NR
2018	Kirchhof et al111	AXAFA-AFNET 5	674	Uninterrupted apixaban vs uninterrupted VKA	3.1% vs 4.4%	NR	0.6% vs 0%	NR
2019	Hohnloser et al58	ELIMINATE-AF	614	Uninterrupted edoxaban vs uninterrupted VKA	2.4% vs 1.7%	>0.05	0.3% vs 0%	NR
2019	Nogami et al60	ABRIDGE-J	442	Minimally interrupted dabigatrana vs uninterrupted VKA	1.4% vs 5.0%	0.03	0% vs 0.5%	NR
Meta-analyses including Asian patients
2018	Cardoso et al62	Meta-analysis	4,962	Uninterrupted NOAC vs uninterrupted VKA	0.9% vs 2% (OR: 0.50; 95% CI: 0.30-0.84)	<0.01	0.08% vs 0.16% (OR: 0.66; 95% CI: 0.19-2.30)	>0.05
2018	Ge et al63	Meta-analysis	12,644	Uninterrupted NOAC vs uninterrupted VKA	OR: 0.66 (95% CI: 0.45-0.96)	0.028	OR: 1.05 (95% CI: 0.44-2.52)	0.916

ABRIDGE-J = Ablation Perioperative Dabigatran in Use Envisioning in Japan; AXAFA-AFNET 5 = Apixaban During Atrial Fibrillation Catheter Ablation- Atrial Fibrillation Network 5; COMPARE = Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation Patients Undergoing Catheter Ablation; ELIMINATE-AF = Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Catheter Ablation; RE-CIRCUIT = Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation; VENTURE-AF = A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy; other abbreviations as in Tables 1, 4, and 7.

^aHolding of 1 or 2 doses.